Fidelity International’s Adamas Pharmaceuticals ADMS Stock Holding History

Fidelity International’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-45,592	Closed	-$1.54M	–	543
2017 Q4	$1.54M	Sell	45,592 -69,262	-60%	-$1.93M	﹤0.01%	472
2017 Q3	$2.43M	Sell	114,854 -65,253	-36%	-$1.2M	0.01%	439
2017 Q2	$3.15M	Hold	180,107	–	–	0.01%	423
2017 Q1	$3.15M	Hold	180,107	–	–	0.01%	440
2016 Q4	$3.04M	Hold	180,107	–	–	0.01%	436
2016 Q3	$2.96M	Hold	180,107	–	–	0.01%	434
2016 Q2	$2.73M	Buy	180,107 +29,148	+19%	+$481K	0.01%	436
2016 Q1	$2.18M	Hold	150,959	–	–	0.01%	427
2015 Q4	$4.28M	Hold	150,959	–	–	0.01%	388
2015 Q3	$2.53M	Sell	150,959 -62,384	-29%	-$1.42M	0.01%	426
2015 Q2	$5.59M	Buy	213,343 +93,480	+78%	+$1.82M	0.02%	407
2015 Q1	$2.1M	Buy	+119,863	New	+$2.05M	0.01%	451

Other funds holding ADMS

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BWCA

Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity International's ADMS Position: Q1 2018 in Review

Fidelity International sold out of Adamas Pharmaceuticals (ADMS) in Q1 2018, closing a stake of 45,592 shares — an estimated $1.54M sold.

Fidelity International first reported a position in ADMS in Q1 2015 and held it in 12 quarters. The position peaked at $5.59M in Q2 2015. 118 funds tracked by Wall St. Rank hold ADMS as of Q1 2018.

Fidelity International reported no remaining Adamas Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Fidelity International sold 45,592 Adamas Pharmaceuticals shares in Q1 2018, an estimated $1.54M.
Fidelity International first reported a position in Adamas Pharmaceuticals in Q1 2015 and held it in 12 quarters.
Fidelity International's Adamas Pharmaceuticals position peaked at $5.59M in Q2 2015.
118 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2018.

Based on Fidelity International's 13F filing for Q1 2018, filed 14 May 2018.